Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status
Top Cited Papers
- 11 May 2020
- journal article
- research article
- Published by Elsevier BV in Pharmacological Research
- Vol. 158, 104899
- https://doi.org/10.1016/j.phrs.2020.104899
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Gilead
- BMS
This publication has 28 references indexed in Scilit:
- First Case of 2019 Novel Coronavirus in the United StatesThe New England Journal of Medicine, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNature Communications, 2020
- Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus InfectionThe Journal of Infectious Diseases, 2019
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading ExoribonucleasemBio, 2018
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant dataThe Lancet Respiratory Medicine, 2014